The treatment of hepatitis C has undergone a significant boom since the advent of direct acting antivirals (DAA). Indeed, the interferon-ribavirin combination that has been used to treat hepatitis C has a virological ...The treatment of hepatitis C has undergone a significant boom since the advent of direct acting antivirals (DAA). Indeed, the interferon-ribavirin combination that has been used to treat hepatitis C has a virological response in only 45% of cases with significant side effects. The advent of direct-acting antivirals has changed the prognosis of cirrhotic patients with hepatitis C. DAAs have ensured a sustained viral response in the majority of patients. Our work aims to see the evolution of hepatitis C patients at the cirrhosis stage under DAA. We conducted a retrospective study over 15 years (January 2009, January 2024) including all patients with post-viral cirrhosis C, whom we divided into two groups: group A, cirrhotic patients who received ribavirin and interferon, and group B, patients on DAA. From January 2009 to January 2024, we conducted a study of 182 patients with viral hepatitis C, including 102 cirrhotic patients. The mean age was 55 years. 66% of patients were initially treated with the ribavirin interferon combination, while 34% received direct-acting antivirals (DAAs). Since the introduction of DAAs, the most commonly used regimens have been sofosbuvir/daclatasvir with or without ribavirin and sofosbuvir/ledipasvir with or without ribavirin. Group A achieved sustained virological response (SVR) in 60% of cases, with notable side effects. In Group B, SVR was 98.18%, with improved tolerability and fewer side effects than previous treatments. Fifteen patients developed hepatocellular carcinoma (HCC), with a significantly lower mortality rate in those treated with DAAs compared with pegylated dual therapy (p: 0.001).展开更多
哮喘控制测试(Asthma Control Test,ACT)评分作为评估哮喘控制水平调查问卷中的一种,可评估哮喘患者评分时前4周的控制情况,以其简便、快捷、实用等优点受到临床医师及患者的青睐。近年来,随着对ACT评分研究的进一步深入,发现其不仅在...哮喘控制测试(Asthma Control Test,ACT)评分作为评估哮喘控制水平调查问卷中的一种,可评估哮喘患者评分时前4周的控制情况,以其简便、快捷、实用等优点受到临床医师及患者的青睐。近年来,随着对ACT评分研究的进一步深入,发现其不仅在评估哮喘控制水平方面具有重要作用,而且还具有预测哮喘未来风险等功能。本文就ACT评分在哮喘研究中的应用做一综述。展开更多
目的系统评价不同中医外治法联合常规治疗干预哮喘非急性发作期的临床疗效。方法计算机检索中国知网(CNKI)、万方(Wanfang Data)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、EMbase、Cochrane Library、PubMed和Web of Science数...目的系统评价不同中医外治法联合常规治疗干预哮喘非急性发作期的临床疗效。方法计算机检索中国知网(CNKI)、万方(Wanfang Data)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、EMbase、Cochrane Library、PubMed和Web of Science数据库,检索时间为建库至2024年11月27日,搜索公开发表的采用中医外治法联合常规治疗干预哮喘的随机对照试验(Randomized controlled trial,RCT)。经文献筛选、资料提取、质量评价后,使用STATA 18.0软件进行网状Meta分析。结果最终纳入45篇文献,共涉及10种中医外治法。网状Meta分析结果显示:在提高总有效率方面,常规治疗+穴位贴敷+耳穴压豆效果最佳;提高哮喘控制测试(Asthma control test,ACT)评分方面,常规治疗+针刺疗效最佳;改善第一秒用力呼气量(Forced expiratory volume in one second,FEV1)水平方面,常规治疗+穴位贴敷+中药穴位注射效果最佳。结论与常规治疗相比,采用不同中医外治法联合常规治疗干预哮喘可获得更好的治疗效果。其中,穴位疗法结合常规治疗效果最佳,但仍需更多高质量、规范化、大样本的RCT研究进行验证。展开更多
目的观察中药穴位敷贴治疗支气管哮喘的临床疗效。方法将2014年1月—2015年1月期间该院门诊治疗的140例支气管哮喘患者随机分为观察组和对照组各70例。观察二组治疗前后临床症状治疗情况、ACT评分(Asthma Control Test)、肺功能变化情...目的观察中药穴位敷贴治疗支气管哮喘的临床疗效。方法将2014年1月—2015年1月期间该院门诊治疗的140例支气管哮喘患者随机分为观察组和对照组各70例。观察二组治疗前后临床症状治疗情况、ACT评分(Asthma Control Test)、肺功能变化情况。结果观察组患者总有效率为87.14%,对照组患者总有效率为67.14%,二组差异有统计学意义(P<0.05)。观察组ACT评分明显高于对照组,二者相比差异有统计学意义(P<0.05)。观察组FEV1%和PEF%和MMEF75/25%明显高于对照组,差异具有统计学意义(P均<0.05)。结论中药穴位敷贴治疗支气管哮喘,可有效改善支气管哮喘的症状,减轻炎性反应,改善肺功能,提高生活质量,且该方法安全、方便、效果显著,值得推广应用。展开更多
文摘The treatment of hepatitis C has undergone a significant boom since the advent of direct acting antivirals (DAA). Indeed, the interferon-ribavirin combination that has been used to treat hepatitis C has a virological response in only 45% of cases with significant side effects. The advent of direct-acting antivirals has changed the prognosis of cirrhotic patients with hepatitis C. DAAs have ensured a sustained viral response in the majority of patients. Our work aims to see the evolution of hepatitis C patients at the cirrhosis stage under DAA. We conducted a retrospective study over 15 years (January 2009, January 2024) including all patients with post-viral cirrhosis C, whom we divided into two groups: group A, cirrhotic patients who received ribavirin and interferon, and group B, patients on DAA. From January 2009 to January 2024, we conducted a study of 182 patients with viral hepatitis C, including 102 cirrhotic patients. The mean age was 55 years. 66% of patients were initially treated with the ribavirin interferon combination, while 34% received direct-acting antivirals (DAAs). Since the introduction of DAAs, the most commonly used regimens have been sofosbuvir/daclatasvir with or without ribavirin and sofosbuvir/ledipasvir with or without ribavirin. Group A achieved sustained virological response (SVR) in 60% of cases, with notable side effects. In Group B, SVR was 98.18%, with improved tolerability and fewer side effects than previous treatments. Fifteen patients developed hepatocellular carcinoma (HCC), with a significantly lower mortality rate in those treated with DAAs compared with pegylated dual therapy (p: 0.001).
文摘哮喘控制测试(Asthma Control Test,ACT)评分作为评估哮喘控制水平调查问卷中的一种,可评估哮喘患者评分时前4周的控制情况,以其简便、快捷、实用等优点受到临床医师及患者的青睐。近年来,随着对ACT评分研究的进一步深入,发现其不仅在评估哮喘控制水平方面具有重要作用,而且还具有预测哮喘未来风险等功能。本文就ACT评分在哮喘研究中的应用做一综述。
文摘目的系统评价不同中医外治法联合常规治疗干预哮喘非急性发作期的临床疗效。方法计算机检索中国知网(CNKI)、万方(Wanfang Data)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、EMbase、Cochrane Library、PubMed和Web of Science数据库,检索时间为建库至2024年11月27日,搜索公开发表的采用中医外治法联合常规治疗干预哮喘的随机对照试验(Randomized controlled trial,RCT)。经文献筛选、资料提取、质量评价后,使用STATA 18.0软件进行网状Meta分析。结果最终纳入45篇文献,共涉及10种中医外治法。网状Meta分析结果显示:在提高总有效率方面,常规治疗+穴位贴敷+耳穴压豆效果最佳;提高哮喘控制测试(Asthma control test,ACT)评分方面,常规治疗+针刺疗效最佳;改善第一秒用力呼气量(Forced expiratory volume in one second,FEV1)水平方面,常规治疗+穴位贴敷+中药穴位注射效果最佳。结论与常规治疗相比,采用不同中医外治法联合常规治疗干预哮喘可获得更好的治疗效果。其中,穴位疗法结合常规治疗效果最佳,但仍需更多高质量、规范化、大样本的RCT研究进行验证。
文摘目的观察中药穴位敷贴治疗支气管哮喘的临床疗效。方法将2014年1月—2015年1月期间该院门诊治疗的140例支气管哮喘患者随机分为观察组和对照组各70例。观察二组治疗前后临床症状治疗情况、ACT评分(Asthma Control Test)、肺功能变化情况。结果观察组患者总有效率为87.14%,对照组患者总有效率为67.14%,二组差异有统计学意义(P<0.05)。观察组ACT评分明显高于对照组,二者相比差异有统计学意义(P<0.05)。观察组FEV1%和PEF%和MMEF75/25%明显高于对照组,差异具有统计学意义(P均<0.05)。结论中药穴位敷贴治疗支气管哮喘,可有效改善支气管哮喘的症状,减轻炎性反应,改善肺功能,提高生活质量,且该方法安全、方便、效果显著,值得推广应用。
